[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shiyou Wei\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,69,97,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645059","phase-4-ed90-of-tegileridine-combined-with-propofol-for-painless-gastroscopy-100645059",false,"NCT07678411","ED90 of Tegileridine Combined With Propofol For Painless Gastroscopy","Determination of The 90% Effective Dose of Tegileridine Combined With Propofol for Gastroscopy in Patients of Different Ages: A Biased-Coin Up-and-down Design Study","Inclusion Criteria:\n\n* Outpatients scheduled for elective painless gastroscopy\n* Age ≥ 18 years old\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body mass index (BMI) between 18.5 and 29.9 kg\u002Fm²\n\nExclusion Criteria:\n\n* Resting SBP ≥ 160 mmHg, DBP ≥ 110 mmHg, or heart rate ≥ 110 beats\u002Fmin on admission to endoscopy room\n* Continuous opioid medication use for more than 2 weeks within 6 months before the procedure\n* Known hypersensitivity or allergic reaction to tegileridine, propofol or any excipients of the two drugs\n* Diagnosed psychiatric disorders or inability to communicate and cooperate with study assessment","ALL","18 Years",{"count":19,"type":20},108,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This single-group, open-label, biased-coin up-and-down sequential dose-finding trial aims to determine the 90% effective dose (ED90) of intravenous tegileridine combined with fixed-dose propofol to eliminate body movement, cough and excessive hemodynamic fluctuations during gastroscopy insertion in adult patients stratified into young (18-65 years) and elderly (≥65 years) subgroups. All subjects receive intravenous tegileridine followed by 2 mg\u002Fkg propofol for sedation induction. The initial tegileridine dose is 5 μg\u002Fkg with a 1 μg\u002Fkg dose step. Dose adjustment follows biased-coin algorithm: dose increases by 1 μg\u002Fkg if positive response occurs; if negative response, there is an 11% probability to decrease dose by 1 μg\u002Fkg. The trial will be terminated when 45 successful cases are accrued in each age subgroup. Primary outcome is ED90 of tegileridine calculated via central ordinal regression. Secondary outcomes include total propofol consumption, MOAA\u002FS sedation score, intraoperative blood pressure and heart rate changes, and incidence of perioperative adverse events within 24 hours post-procedure.",[26,27],"Painless Gastroscopy Perioperative Sedation","Upper Gastrointestinal Tract Lesions",[29,30,31,32,33],"Tegileridine","µ-opioid receptor G-protein-biased agonist","Biased-coin sequential allocation","gastroscopy","ED90","NOT_YET_RECRUITING","2026-06-25",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":20},"2026-07-05",{"date":42,"type":20},"2026-07-27",{"name":44,"class":45},"Shiyou Wei","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100644147","phase-4-ed90-of-tegileridine-combined-with-propofol-for-lma-insertion-100644147","NCT07665151","ED90 of Tegileridine Combined With Propofol for LMA Insertion","90% Effective Dose of Tegileridine Combined With Propofol for Inhibiting Laryngeal Mask Airway Insertion Responses in Patients of Different Ages: A Biased-Coin Sequential Allocation Dose-Finding Study","Inclusion Criteria:\n\n* Elective surgery requiring general anesthesia with laryngeal mask airway insertion\n* Age ≥ 18 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n\nExclusion Criteria:\n\n* At rest in the operating room, systolic blood pressure ≥ 160 mmHg or - diastolic blood pressure ≥ 110 mmHg or heart rate ≥ 110 bpm\n* Continuous opioid medication for more than 2 weeks within half a year before surgery\n* Known allergy or hypersensitivity to tegileridine or any study medication components\n* History of psychiatric illness or inability to communicate effectively",{"count":19,"type":20},[23],"This is a prospective two-group dose-finding trial using biased-coin sequential up-and-down design. We plan to enroll 108 patients who need general anesthesia with laryngeal mask airway placement, divided into young group (18-65 years old) and elderly group (65 years old and older). All patients will receive tegileridine combined with fixed-dose propofol for anesthesia induction. The main goal is to find the 90% effective dose (ED90) of tegileridine that can fully block body movement, cough, tearing and unstable blood pressure\u002Fheart rate during laryngeal mask insertion. We will also record cough rate, hemodynamic changes, sedation depth and all perioperative adverse reactions to provide safe dosing reference for different age patients in clinical anesthesia.",[58],"Elective Surgery Requiring Laryngeal Mask Airway General Anesthesia",[29,30,60,31,33],"laryngeal mask airway","2026-06-24",{"date":63,"type":38},"2026-06-29",{"date":65,"type":20},"2026-07-10",{"date":67,"type":20},"2026-08-10",{"name":44,"class":45},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100642014","phase-4-fospropofol-disodium-versus-propofol-for-patient-satisfaction-in-ureteroscopy-100642014","NCT07659132","Fospropofol Disodium Versus Propofol for Patient Satisfaction in Ureteroscopy","Fospropofol Disodium Versus Propofol on Patient Satisfaction in Patients Undergoing Ureteroscopy：A Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing elective ureteroscopic surgery\n* Aged between 18 and 90 years old\n* American Society of Anesthesiologists (ASA) physical status classification grade I to III\n\nExclusion Criteria:\n\n* Known allergy to propofol, fospropofol or their excipients\n* Severe cardiopulmonary insufficiency\n* Hepatic and renal dysfunction.Hepatic or renal insufficiency. Hepatic dysfunction: alanine aminotransferase (ALT) \\> 50 U\u002FL, or aspartate aminotransferase (AST) \\> 40 U\u002FL, or total bilirubin (TBIL) ≥ 19 μmol\u002FL; Renal dysfunction: serum creatinine (Cr) \\> 112 μmol\u002FL, or blood urea nitrogen (BUN) \\> 7.1 mmol\u002FL, or receiving dialysis within 28 days before surgery.\n* Pregnancy, lactation, potential pregnancy or planned pregnancy\n* Subjects who refuse to participate","90 Years",{"count":78,"type":20},190,[23],"This single-center single-blind randomized trial compares fospropofol disodium and propofol for anesthesia in elective ureteroscopy patients. A total of 190 eligible adults will be randomly divided into two groups at 1:1 ratio with identical intraoperative maintenance protocols. The primary outcome is 24-hour postoperative anesthesia satisfaction assessed by ISAS scale; secondary and safety endpoints include injection pain, intraoperative hemodynamic events and various perioperative adverse reactions. This study explores the clinical efficacy and safety of the two sedatives to guide rational clinical medication.",[82,83],"Anesthesia for Urologic Endoscopic Surgery","Urinary Calculi",[85,86,87,88,89],"fospropofol disodium","propofol","ureteroscopy","anesthesia satisfaction","sedation","2026-06-19",{"date":61,"type":38},{"date":93,"type":20},"2026-06-26",{"date":95,"type":20},"2026-09-26",{"name":44,"class":45},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":46},"100642256","phase-4-oliceridine-vs-sufentanil-for-cough-during-anesthesia-induction-100642256","NCT07660380","Oliceridine vs Sufentanil for Cough During Anesthesia Induction","Oliceridine vs Sufentanil for Cough During General Anesthesia Induction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 99 years.\n* American Society of Anesthesiologists (ASA) physical status classification I, II, or III.\n* Body mass index (BMI) between 18.5 and 28.0 kg\u002Fm².\n* Scheduled for elective surgery under general anaesthesia.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative upper respiratory tract infection symptoms (e.g., cough, expectoration, or fever) or a history of bronchial asthma or other conditions associated with increased airway reactivity.\n* Severe cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction, or serious arrhythmia) or hepatic or renal dysfunction.\n* Long-term opioid use, defined as continuous opioid use for more than 2 weeks within the 3 months prior to surgery.\n* Known hypersensitivity to any study drug or anaesthetic agent used in this protocol.\n* Anticipated difficult airway requiring awake intubation.\n* Pregnancy or breastfeeding.","99 Years",{"count":106,"type":20},62,[23],"Sufentanil is the most widely used opioid analgesic for general anaesthesia induction; however, rapid intravenous bolus injection frequently triggers sufentanil-induced cough (SIC). In high-risk patients, SIC can cause abrupt elevation of intracranial and intraocular pressure and severe haemodynamic instability, posing a meaningful safety risk during the induction period.\n\nOliceridine, the first G protein-biased μ-opioid receptor agonist approved by the Food and Drug Administration in 2020, provides analgesia through μ-receptor activation while substantially reducing β-arrestin-2 recruitment. This biased signalling profile is hypothesised to raise the excitation threshold of airway C-fibres and thereby reduce the incidence of cough.\n\nThis prospective, single-centre, randomised, double-blind, parallel-group controlled trial directly compares oliceridine with sufentanil for general anaesthesia induction with respect to cough incidence, cough severity, haemodynamic responses, and perioperative safety, with the aim of providing evidence-based guidance for opioid selection during induction.",[110,111],"Cough","Anesthesia",[113,114,115,116,117],"Oliceridine","Sufentanil","Sufentanil-induced cough","G protein-biased agonist","Anesthesia induction","2026-06-18",{"date":120,"type":38},"2026-06-23",{"date":122,"type":20},"2026-06-22",{"date":37,"type":20},{"name":44,"class":45},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":46},"100618509","eoib-for-pain-after-laparoscopic-cholecystectomy-100618509","NCT07332546","EOIB for Pain After Laparoscopic Cholecystectomy","External Oblique Intercostal Block for Postoperative Pain After Laparoscopic Cholecystectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18-85 years, regardless of gender\n* American Society of Anesthesiologists (ASA) physical status classification I-III\n* Scheduled for elective laparoscopic cholecystectomy\n* Ability to use the intravenous patient-controlled analgesia (IV PCA) system\n\nExclusion Criteria:\n\n* Hepatic disease (e.g., liver enzyme levels ≥ 2× the upper limit of normal)\n* Renal disease (e.g., serum creatinine levels ≥ 2× the upper limit of normal)\n* Allergy or known hypersensitivity to local anesthetics\n* Females who are pregnant or lactating\n* Conversion to open surgery\n* Coagulopathy or current use of anticoagulant medications\n* Opioid use for more than 2 weeks in the past 6 months","85 Years",{"count":134,"type":20},56,[136],"NA","This prospective, randomized, controlled, assessor-blinded trial will evaluate whether bilateral ultrasound-guided external oblique intercostal block (EOIB) reduces postoperative opioid consumption and improves pain control after laparoscopic cholecystectomy, compared with no block.",[139,140],"Postoperative Pain","Laparoscopic Cholecystectomy",[142,143,144,145],"External oblique intercostal block","Ultrasonography, Interventional","Nerve Block","Quality of recovery (QoR-15)","RECRUITING","2026-06-06",{"date":149,"type":38},"2026-06-09",{"date":151,"type":38},"2026-01-15",{"date":40,"type":20},{"name":44,"class":45},""]